Purposeful
& Passionate

In a dynamic and rapidly changing industry, GSL has seized on the opportunity to apply superior scientific expertise,  our unique products and patented technologies to enhance quality and efficacy in the development of cannabinoid medicines, products and plant cultivation.

SUPERIOR SCIENCE, INSPIRED PRODUCTS AND EXCEPTIONAL OUTCOMES

We are a team of experienced business professionals, entrepreneurs, doctors, professors, researchers and administrators with a common goal: to drive innovation, better products, and better outcomes in the cannabinoid industry, from plant to patient and all stages in between.

"We’re revolutionizing the cannabinoid industry with experienced leadership, thoughtful innovation and consistent, quality products."

We are innovators in the development of new, highly effective and precise cannabinoid medicines and products

We are thought leaders, advancing research to unlock the full potential of cannabinoid compounds and therapies

We deliver quality and efficacy to the industry’s cultivators by providing product solutions and plant science expertise

Partner Institutions

Forging relationships with innovative partner institutions to further our research is not only good for business, it’s GSL’s long-term strategy. Through our partners, we gain access to a community of researchers, some of whom lead trials that help validate results. Our partners including the following esteemed institutions:

Purposeful
& Passionate

In a dynamic and rapidly changing industry, GSL has seized on the opportunity to apply superior scientific expertise,  our unique products and patented technologies to enhance quality and efficacy in the development of cannabinoid medicines, products and plant cultivation.

SUPERIOR SCIENCE, INSPIRED PRODUCTS AND EXCEPTIONAL OUTCOMES

We are a team of experienced business professionals, entrepreneurs, doctors, professors, researchers and administrators with a common goal: to drive innovation, better products, and better outcomes in the cannabinoid industry, from plant to patient and all stages in between.

"We’re revolutionizing the cannabinoid industry with experienced leadership, thoughtful innovation and consistent, quality products."

We are innovators in the development of new, highly effective and precise cannabinoid medicines and products

We are thought leaders, advancing research to unlock the full potential of cannabinoid compounds and therapies

We deliver quality and efficacy to the industry’s cultivators by providing product solutions and plant science expertise

Partner Institutions

Forging relationships with innovative partner institutions to further our research is not only good for business, it’s GSL’s long-term strategy. Through our partners, we gain access to a community of researchers, some of whom lead trials that help validate results. Our partners including the following esteemed institutions:

Green Sky Labs Leadership

GREG BARON - President

BComm (Finance & Real Estate) with over 25 years of experience in commercial real estate with an extensive background in both equity and debt finance, operations and administration. Greg has negotiated and financed over $600M in real estate acquisitions.

A significant investor in Green Sky Labs with a people-focused leadership style.

REHAN HUDA (M.A.) - Chief Executive Officer

Having over 20 years of experience in investment banking, entrepreneurship, and corporate finance, Rehan Huda brings a brings knowledge and leadership to the company. He has helped structure and fund a number of leading edge companies in the biotechnology and information technology space.

Mr. Huda held various positions within the Canadian federal government including Senior Economist for the Department of Finance and Senior Analyst for the Natural Resources and Industry Departments. In addition, Mr. Huda was a recipient of the Canadian Government’s Public Service Award of Excellence for his financial and economic analysis related to the awarding of operating licenses to wireless telecommunication service providers.

DWAYNE DEJONG (P.ENG, MBA) – Chief Operating Officer

Dwayne brings over 25 years of experience and leadership, focused on developing and delivering technology-driven business services and solutions, providing outstanding client service, and driving profitable revenue growth in several different industries. Prior to joining Green Sky Labs in 2021, Dwayne held several leadership positions in Sales, Operations, Engineering and Finance at IBM, Bell Canada, Celestica and Lucent Technologies and has been an early investor and advisor for several Biotech/Innovation Companies.

Dwayne holds a Bachelor of Engineering and Master of Business Administration degrees from McMaster University.

SHAMSHAD HUSAIN (CPA -US) - Chief Financial Officer

Shamshad is a finance professional with extensive accounting, financial and regulatory reporting expertise. He has over 30 years of experience working mainly at professional accounting firms PWC and Deloitte, and banks such as CIBC, TD and Scotiabank. His work experience includes mainly financial reporting, controllership functions, capital management, internal controls and project management.

Shamshad is a CA (Pakistan) and a CPA from the US

My Next Health Leadership

KASHIF KHAN (B.Sc.) - Chief Executive Officer

Kashif Khan is an entrepreneur and investor who has built, run, and scaled businesses across a range of industries. He is the founder and Chief Executive Officer of My Next Health. Mr. Khan currently serves as the CEO of The DNA Company and is also the co-founder and CEO of Youtrients, a company providing personalized supplement formulations based on unique DNA analysis.

DR. MANSOUR (Ph.D.) - Chief Scientific Officer

Dr. Mohammed is the Founder and President of ManaGene and is widely regarded as a pioneer in medical genomics. Dr. Mohammed is credited with discovering one of two genomic pathways that define drug resistance to the Novartis-developed leukemia therapy and co-published these findings in the journal Science (2001). Dr. Mohammed was instrumental in the development and commercialization of the industry’s first available comparative genomic hybridization (CGH) arrays.

DR. DAVID LIEPERT (MD) - Chief Medical Officer

Stanford trained expert in critical care medicine with over 30 years of experience as a board-certified specialist in anesthesiology. Part of the Calgary Quality Council and is an advisor with regards to surgical quality throughout the Province of Alberta. Director of Quality Assurance and Quality Improvement for the Cumming School of Medicine Department of Anesthesia, Pain and Peri- Operative Medicine as well as AHS Calgary Zone Safety. Quality Lead and National Surgical Quality Improvement Program Champion and a member of the Alberta Pain Network.

Agentix Biosciences Leadership

RUDY MAZZOCCHI (M.Sc.) - Chief Executive Officer

Holds over 30 years of senior management and financing experience in the medical technology industry. Has founded several companies in the cardiology, neurosurgery and ophthalmology fields. Author of over 100 patents. Recipient of E&Y Entrepreneur of the Year award

MARTIN SCHROEDER – Chief Scientific Officer

Martin brings over 25 years of success in general management, technical R&D management, marketing, corporate finance and business development. He has founded of numerous highly valued companies and startups.

SALMAN HODA (MBA) - Senior Vice President, Pharmaceuticals

Over 15 years of pharmaceutical industry experience spanning operations, marketing and business development. Prior responsibilities involved identifying and evaluating assets for investment, building relationships and negotiating agreements. Lead teams of scientific, medical, legal, technical and commercial professionals to comprehensively evaluate product portfolios.

PAUL CARPANINI (MBA, CFA) – Chief Executive Officer

Paul brings over 25 years of experience in marketing institutional investment management services, mergers and acquisitions and international market expansion. Through his experience and qualifications, he has a sound and thorough understanding in business practices and demonstrated ability helping with entrepreneurial start-up ventures. Formerly working in Corporate Business Development, Paul is committed to help uncover new specialized markets and niche opportunities to grow the business.

DAN POLONENKO (Ph.D.) - Director

Dr. Polonenko is a patent agent registered with the Canadian Intellectual Property Office (CIPO) and the USPTO. Dr. Polonenko works in Gowling WLG’s Calgary office and his practice includes patent drafting and prosecution in the fields of biotechnology, health, and medical devices, among others. Dr. Polonenko has co-authored 20 peer-reviewed scientific publications, several book chapters and was a co-inventor of six issued patent families. Dan has been recognized in several IAM Strategy and IAM Patent awards.

TONY DURST (Ph.D.) - Scientific Advisor

Professor Emeritus at the University of Ottawa Dr. Durst is a co-inventor on 14 patents and has received several awards including the Queen Elizabeth 60th Silver Jubilee medal in 2013. Dr. Durst was chair of three NSERC grants committees; he also served as member of US National Institute of Cancer major research program committees. During the past twenty years his research has focused on the isolation, evaluation and modification of natural products with potential medical application obtained from plants.

MIKE HRYTSAK (Ph.D.) - Scientific Advisor

Ph.D. in organic chemistry from the University of Ottawa in 1988 under the thesis supervision of Dr. Tony Durst. Dr. Hrytsak worked for many years with Dupont Pharmaceuticals and Bristol-Myers Squibb in the R&D of organic chemical processes for active pharmaceutical ingredients (API). Dr. Hrytsak has broad experience in the preparation of API under cGMP at kilo and pilot plant scale.

Kalmex Leadership

STAMOS KATOTAKIS (M. Eng., MBA) - President & CEO, Director

Mr. Katotakis is a chemical engineer with an exceptional record in the technology space. As the founder and CEO of Financial Models Company (“FMC”), he guided the company from its infancy to the status of a public company with over 500 employees and one of the pre-eminent world-wide suppliers of investment management software.

SHARIEF ZAMAN (B.Sc.) - Chief Operating Officer

Mr. Zaman is the former Managing Director, Southeast Asia and Middle East Region at Orbixa Capital International and Vice President of Orbixa Management Services, Inc. He has led operations across many countries with Orbixa’s advanced transaction technologies for traders in the financial services sector.

FAKHIR BAIG (Ph.D.) - Director

Mr. Baig is the CEO of Petro Sep, an industry leader in applying membrane technology to a wide variety of separation projects. Petro Sep has built over 100 large scale plants in many parts of the world, ranging from extraction to petroleum and water purification.

Green Sky Labs Board of Directors

RICHARD GRAW- Chairman of the Board

JD, senior legal counsel with extensive experience as a corporate/ commercial, regulatory and administrative law lawyer having held prominent positions with both industry and government, as well as in private practice.
Ongoing advisor to management and the board since incorporation.

GREG BARON- President and Board Member

BComm (Finance & Real Estate) with over 25 years of experience as an entrepreneur in commercial real estate and an extensive background in both equity and debt finance, operations and administration.
Negotiated and financed over $600M in real estate acquisitions.
A significant investor in GSL with a people-focused leadership style.

REHAN HUDA- Chief Executive Officer and Board Member

M.A. (Economics), with over 20 years of experience in investment banking, entrepreneurship and corporate finance.
Structured and funded a number of leading-edge companies in the bio-tech and IT industries.
Guest speaker on finance at a variety of conferences and universities across Canada and internationally.

JOHN AYANOGLOU - Board Member

John has served as Chief Financial Officer (CFO) of four financial services firms, three of which were publicly-listed companies, including Equitable Group (and its wholly-owned OSFI registered financial institution, currently Canada’s 9th largest schedule I bank). He has built and inspired successful teams and worked with Boards, investment bankers and others to cumulatively raise over $1 billion in common, preferred, debenture and other financing. Prior to this, John practiced with PricewaterhouseCoopers LLP (PwC), in Toronto and Boston. John holds directorships with DX Financial Mortgage Investment Corporation and Omega WealthGuard, which is a private company. He holds a double specialist degree in Commerce and Economics from the University of Toronto, and is a chartered accountant and a member of CPA Canada (CA/CPA). John has also received his ICD.D designation from the Institute of Corporate Directors at the Rotman School of Business.

ROBERT GUO- Board Member

Mr. Robert Guo is currently the President Sixty Degree Capital, a venture capital and private equity firm, Mr. Guo is a seasoned and insightful venture capital and private equity investor with years of experience investing in international markets, Prior to this, Mr. Guo was the President of an investment firm and formerly sat as a member of the Board of Directors of various public and private companies.

JIM PETERSON- Board Member

Jim is a Canadian former politician. He was a Liberal member of the House of Commons of Canada from 1980 to 1984 and again from 1988 to 2007 who represented the northern Toronto riding of Willowdale. He served in the cabinet of Jean Chrétien as Secretary of State (International Financial Institutions) and the cabinet of Paul Martin as Minister of International Trade.